New Study Reports Reduction in Rehospitalization After Lung Transplantation Utilizing Paragonix Preservation Devices

Findings from the GUARDIAN-Lung Registry highlight statistically significant reductions in hospital readmissions and acute rejection rates with advanced hypothermic lung preservation technologies

Excerpt from the Press Release:

WALTHAM, Mass.–(BUSINESS WIRE)–Paragonix Technologies, a leader in organ transplant technologies and organ procurement services, announced new lung preservation research at the 45^th ISHLT Annual Meeting and Scientific Sessions. Drawing on data from the GUARDIAN-Lung Registry, the first and largest global clinical registry for studying lung preservation, investigators presented the largest analysis of the registry to date, demonstrating that Paragonix hypothermic preservation significantly reduced rehospitalizations and acute rejection after transplant.¹

The lung research presented across the four-day conference observed significant improvements in association with the LUNGguard^® and BAROguard^® Donor Lung Preservation Systems over the traditional standard of preservation, static ice storage. GUARDIAN investigators presented four new abstracts on lung preservation, adding to the growing pool of Paragonix research that first began in 2020.

The overall outcomes of the LUNGguard System were presented by Dr. Nathaniel Langer, Surgical Director of Lung Transplantation at Massachusetts General Hospital. Composed of a total of 1,160 lung transplant adults from 15 international transplant centers, investigators propensity-matched 608 patients into two comparative cohorts to compare advanced preservation directly against ice storage.

Click the button below to read the entire Press Release:

Continue Reading The Press Release